Other Deal Trends 2026: Activity Up 3900% in 6 Months

39 deals in six months — up from zero in the prior period. That's the headline number for other deal trends 2026, a category that captures platform technology transactions, tools licensing, AI-driven discovery partnerships, and non-traditional collaborations that don't fit neatly into therapeutic area buckets. The +3900% surge isn't a rounding artifact; it reflects a structural reorientation in how Big Pharma is deploying capital. The bidding war is no longer just for late-stage assets in oncology or immunology — it's for the engines that generate those assets at scale.

The Data — Other Deal Activity, Period over Period

The baseline of zero is worth interrogating. Prior to January 2026, platform and tools deals were either classified under their downstream therapeutic areas or simply weren't occurring at this velocity. The reclassification coincides with a genuine market shift: pharma companies are now structuring deals explicitly around enabling technologies — protein engineering platforms, AI-native drug design, biologics manufacturing capabilities — rather than bundling them as bolt-ons to therapeutic partnerships. When you see 39 transactions materialize in a category that didn't formally exist six months ago, that's not noise. That's a new market forming in real time.

What's Driving the Trend

Pipeline anxiety meets platform economics. The largest pharma companies face a well-documented patent cliff between 2025 and 2028. Humira, Keytruda, Stelara, Eliquis — the math is brutal. But instead of competing in increasingly crowded late-stage asset auctions where upfronts have inflated past rational DCF ranges, a cohort of acquirers has pivoted to buying the means of production. Platform deals offer optionality across multiple programs and therapeutic areas simultaneously, which changes the risk-adjusted math entirely. A single $11.3B platform acquisition can feed a pipeline for a decade; a single $5B asset acquisition feeds it for one indication.

AI-native biology has crossed the credibility threshold. Novartis's deal with Generate:Biomedicines — a company built entirely on machine learning-driven protein design — marks a watershed. Two years ago, AI-bio partnerships were pilot-scale, risk-sharing arrangements with modest upfronts. Today, they're strategic acquisitions. The underlying technology has matured enough that pharma R&D leadership is willing to bet real capital, not exploratory option money. This shift from "innovation theater" to "core infrastructure" is pulling dozens of smaller platform deals into the pipeline behind the mega-transactions.

Regulatory arbitrage is accelerating cross-border structures. YaoPharma's $2.05B total deal value partnership with Pfizer exemplifies a parallel force: Western pharma is licensing capabilities and regional manufacturing platforms from Chinese and Asian partners at a pace that would have been unthinkable during the 2023–2024 decoupling panic. The regulatory environment has quietly normalized. Companies that positioned themselves as China+1 partners are now commanding premium valuations — and the deal structures in this category reflect that, with larger upfronts and milestone-heavy payouts designed to lock in exclusivity. Check how these structures compare against historical norms using our Deal Benchmarks data.

Notable Deals

Bio-Techne / Merck KGaA dominates the dataset and demands scrutiny. The $11.3B total deal value — appearing across multiple filings as the transaction structure was amended — represents Merck KGaA's largest-ever deal and one of the biggest other licensing 2026 transactions on record. Bio-Techne's protein sciences and diagnostics platform gives Merck KGaA vertical integration across biologics development, from target identification through manufacturing reagents. This isn't a licensing deal in the traditional sense; it's an infrastructure acquisition priced like one. The upfront equaling the TDV suggests this was structured as an outright purchase rather than a milestone-laden partnership, which tells you how much strategic urgency Merck KGaA attached to closing.

Generate:Biomedicines / Novartis is the deal to watch for longer-term signaling. Financial terms remain undisclosed, but the strategic logic is loud: Novartis is acquiring generative AI drug design capability as a core competency, not a collaboration. Every pharma company that hasn't made a comparable move is now one cycle behind.

YaoPharma / Pfizer at $150M upfront against $2.05B TDV is a more conventional structure — roughly 7.3% upfront-to-TDV ratio — but the deal itself is unconventional. Pfizer licensing from a Chinese regional player signals confidence in YaoPharma's manufacturing and formulation platform that goes beyond typical geographic market access deals. The milestone-heavy structure suggests Pfizer is buying optionality across multiple products, not a single asset.

What This Means for BD Teams Right Now

If you're selling platform technology, you're in a seller's market — but the window has a shelf life. The 39-deal surge is concentrated in Q2 2026. Once the largest acquirers (Merck KGaA, Novartis, Pfizer) have locked in their platform plays, the competitive tension that's driving valuations evaporates. If you have a differentiated enabling technology — AI-driven discovery, next-gen biologics manufacturing, novel protein engineering — your leverage peaks in the next two to three quarters. After that, pharma BD teams will have checked the box and moved to integrating what they've bought.

If you're buying, move fast and structure smart. The Bio-Techne deal shows what happens when you wait: you pay full TDV upfront because you've lost negotiating leverage to competing bidders. Teams that engaged earlier in 2026 secured better economics. The optimal structure right now is a co-exclusive platform access deal with milestone triggers tied to IND filings, not regulatory approvals — that shifts risk earlier and keeps your total commitment lower. Use the Deal Calculator to model upfront-to-TDV ratios against current benchmarks before you set your opening term sheet.

Deal structures are evolving. Traditional royalty-on-net-sales models don't map well to platform deals where the "product" is a capability, not a molecule. We're seeing more equity-based hybrid structures, co-development agreements with shared IP ownership, and capacity reservation models that look more like semiconductor foundry contracts than pharma licenses. BD teams that can't structure outside the standard playbook will lose mandates to those that can.

Benchmark your deal against current market rates — the spread between median and top-quartile platform deal values has widened dramatically in H1 2026. Use the Ambrosia calculator to see where your transaction sits relative to the 39 deals closed this period and to stress-test your valuation assumptions before entering term sheet negotiations.

Frequently Asked Questions

Why did other deal activity go from zero to 39 in one period?

The jump reflects both a genuine acceleration in platform technology dealmaking and a reclassification effect as the industry adopted more granular deal taxonomy. Prior to January 2026, many platform and tools transactions were categorized under their downstream therapeutic areas. The 39 deals in H1 2026 include AI-driven discovery platforms, biologics manufacturing capabilities, and diagnostic technology licensing — all of which are now tracked as distinct from molecule-specific partnerships. The Bio-Techne/Merck KGaA transaction alone at $11.3B TDV would have skewed any period's data, but the remaining 38 deals confirm this is a broad trend, not a single-deal anomaly.

How should BD teams value platform technology deals differently from traditional asset licensing?

Platform deals require a fundamentally different valuation framework. Instead of risk-adjusted NPV on a single molecule, you're modeling optionality across multiple potential programs — which means the value scales with the breadth of application, not the probability of success for any one candidate. The Bio-Techne deal at $11.3B with upfront equaling TDV suggests acquirers are paying for certainty of access rather than probability-weighted outcomes. BD teams should use scenario-based models with 5–15 potential downstream programs rather than single-indication DCFs. Our Deal Benchmarks include platform-specific comparables that can anchor these models.

Is the +3900% growth rate sustainable into H2 2026?

No. The percentage growth is mathematically exaggerated by the zero baseline, and the largest deals — particularly Bio-Techne/Merck KGaA — represent once-in-a-cycle transactions. However, the absolute number of 39 deals is likely to hold or grow modestly, probably reaching 45–55 by January 2027. The structural drivers — patent cliffs, AI platform maturity, cross-border normalization — are durable. What will change is the average deal size: as the $10B+ platform targets get absorbed, the market will shift toward mid-scale deals in the $500M–$2B TDV range, which is where most BD teams should be focusing their pipeline development right now.